| abstract |
The invention provides in some aspects immunotherapy, such as adoptive cell therapy (eg, T cell therapy), and methods comprising structural or functional analogs or derivatives of thalidomide and/or immunomodulatory compounds such as inhibitors of E3-ubiquitin ligase , compositions and uses. The methods, compositions and uses provided are for administering or using one or more immunomodulatory compounds in combination with T cell therapy, such as genetically engineered T cell therapy, including cells engineered with a recombinant receptor, such as a chimeric antigen receptor (CAR)-expressing T cell. Included for combination therapy comprising Also provided are compositions, methods of administration to a subject, articles of manufacture, and kits for use in the methods. In some aspects, the methods and features of the cells provide for an increase or enhancement of the activity, efficacy, persistence, amplification and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by an immunotherapeutic agent. |